Lifevantage (NASDAQ:LFVN - Get Free Report) will likely be releasing its Q1 2027 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.03 per share and revenue of $40.49 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2027 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.
Lifevantage (NASDAQ:LFVN - Get Free Report) last issued its quarterly earnings data on Thursday, August 27th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.01). Lifevantage had a return on equity of 21.56% and a net margin of 2.78%. The company had revenue of $42.38 million for the quarter, compared to analysts' expectations of $44.00 million. On average, analysts expect Lifevantage to post $0.39 EPS for the current fiscal year and $0.53 EPS for the next fiscal year.
Lifevantage Stock Down 1.7%
Shares of NASDAQ LFVN opened at $5.76 on Tuesday. The company has a market cap of $72.52 million, a P/E ratio of 10.46 and a beta of 0.68. Lifevantage has a 52 week low of $3.90 and a 52 week high of $11.71. The business has a 50-day simple moving average of $6.24 and a two-hundred day simple moving average of $5.91.
Lifevantage Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st were given a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 1st. This represents a $0.20 annualized dividend and a dividend yield of 3.5%. Lifevantage's dividend payout ratio is currently 50.00%.
Insider Buying and Selling
In other Lifevantage news, insider Kristen Cunningham sold 8,901 shares of Lifevantage stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $6.18, for a total transaction of $55,008.18. Following the transaction, the insider directly owned 120,162 shares of the company's stock, valued at approximately $742,601.16. This trade represents a 6.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 13.58% of the stock is owned by insiders.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on LFVN shares. Lake Street Capital increased their price target on shares of Lifevantage from $5.00 to $6.00 and gave the stock a "hold" rating in a report on Friday, August 28th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Lifevantage in a research note on Friday, August 21st. Finally, Zacks Research lowered shares of Lifevantage from a "hold" rating to a "strong sell" rating in a report on Friday, October 16th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and an average target price of $5.50.
Get Our Latest Report on Lifevantage
About Lifevantage
(
Get Free Report)
LifeVantage Corporation is a health and wellness company that develops, markets and distributes dietary supplements and personal-care products. Its product portfolio is designed to support areas such as cellular health, antioxidant defenses, energy, nutrition and skin care.
The company's principal brands have included Protandim, a line of dietary supplements; TrueScience, a skin-care and wellness brand; and Petandim, products formulated for pets. LifeVantage primarily uses a direct-selling business model, distributing its products through independent sales representatives and online channels.
Founded in 2003 and headquartered in Lehi, Utah, LifeVantage serves customers in the United States and selected international markets.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lifevantage, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifevantage wasn't on the list.
While Lifevantage currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.